Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

(2017) Rebecca Mitchell et al.   JNCI-Journal of the National Cancer Institute

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

(2017) Rebecca Mitchell et al.   JNCI-Journal of the National Cancer Institute

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

(2016) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Targeting the mTOR Pathway in Leukemia

(2016) Shira Dinner et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy

(2016) Mohamed A. M. Ali   Molecular Diagnosis & Therapy

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation

(2015) Alessandro Morotti et al.   CELL CYCLE

Targeting PI3K/AKT/mTOR network for treatment of leukemia

(2015) Jessika Bertacchini et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Drug transporters play a key role in the complex process of Imatinib resistance in vitro

(2015) Raquel Alves et al.   LEUKEMIA RESEARCH

L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells

(2015) José Mendes et al.   PATHOLOGY & ONCOLOGY RESEARCH

PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia

(2014) Fang-Fang Huang et al.   PLoS One

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

(2014) Sarah K. Tasian et al.   Frontiers in Oncology

Targeting survival pathways in chronic myeloid leukaemia stem cells

(2013) A Sinclair et al.   BRITISH JOURNAL OF PHARMACOLOGY

Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia

(2013) Fang-Fang Huang et al.   CANCER LETTERS

Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+acute lymphoblastic leukemia cells

(2013) Xi Yang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

(2013) Burhan Hassan et al.   Surgical Oncology Clinics of North America

PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter

(2012) Csilla Hegedüs et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

mTOR inhibitors in cancer therapy

(2012) Yekaterina Y. Zaytseva et al.   CANCER LETTERS

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

(2011) Hilmar Quentmeier et al.   Journal of Hematology & Oncology

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

(2010) Jun Sunayama et al.   STEM CELLS

PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice

(2009) C. Peng et al.   BLOOD

PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells

(2009) Anne-Marie Bleau et al.   Cell Stem Cell

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia

(2009) Manuela Mancini et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

(2008) Bing-Hua Jiang et al.   DRUG RESISTANCE UPDATES